{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:35:52Z","timestamp":1790800552209,"version":"4.1.0"},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Metabolic dysfunction associated steatotic liver disease (MASLD) increases the risk of incident chronic kidney disease (CKD). However, the relative risk of CKD associated with increasing hepatic fibrosis, and consequent mortality risk, remains underexplored in real-world cohorts. In this study, we sought to establish whether hepatic fibrosis is associated with increased CKD risk and explore differences in mortality risk in a cohort of people living with MASLD, contingent on liver fibrosis and CKD status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was an observational study of people who underwent routine liver function testing in Tayside, Scotland. MASLD was defined as: elevated ALT (&gt;30 U\/L) or GGT (&gt;73 U\/L); presence of diabetes, and\/or hypertension, and\/or obesity; weekly alcohol consumption &lt;14 units (112g (+\/-8g) alcohol); and negative screen for other aetiologies. Data was collected from digital health records. We used log-binomial models to quantify the risk of CKD among those with and without fibrosis, and Cox regression models to estimate differences in mortality risk dependent on fibrosis and CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In our cohort (n = 2,046), 1,448 (70.8%) people had MASLD without fibrosis and 598 (29.2%) with fibrosis; 161 (11.1%) and 117 (19.6%) respectively also had CKD. After excluding individuals with structural, autoimmune, or malignant CKD (n = 22), liver fibrosis (n = 593; 18.9% with CKD) was associated with increased CKD risk (\n                      <jats:italic>a<\/jats:italic>\n                      RR = 1.31, 1.04\u20131.64, p = 0.021). Increased mortality risk was observed for those with liver fibrosis (\n                      <jats:italic>a<\/jats:italic>\n                      HR = 2.30, 1.49\u20133.56, p = &lt;0.001) and was higher again among people with both fibrosis and CKD (\n                      <jats:italic>a<\/jats:italic>\n                      HR = 5.07, 3.07\u20138.39, p = &lt;0.014).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Liver fibrosis was an independent risk factor for CKD in this cohort of people living with MASLD. Furthermore, those with MASLD with liver fibrosis had higher risk for mortality and this risk was further elevated among those with co-morbid CKD. Given the increased risk of CKD, and consequent mortality risk, among people living with MASLD fibrosis, renal function screening should be considered within liver health surveillance programmes and guidelines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0299507","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T13:48:21Z","timestamp":1713275301000},"page":"e0299507","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":35,"title":["Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4728-0682","authenticated-orcid":true,"given":"Marc","family":"Gurun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8368-1478","authenticated-orcid":true,"given":"Paul","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sava","family":"Handjiev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aseil","family":"Khatib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Leith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2164-4476","authenticated-orcid":true,"given":"John F.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7586-7712","authenticated-orcid":true,"given":"Christopher J.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"issue":"9","key":"pone.0299507.ref001","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD WORLDWIDE: A systematic review and meta-analysis","volume":"7","author":"K Riazi","year":"2022","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"7","key":"pone.0299507.ref002","article-title":"Global prevalence of chronic kidney disease\u2013a systematic review and meta-analysis.","volume":"11","author":"NR Hill","year":"2016","journal-title":"PLOS ONE."},{"key":"pone.0299507.ref003","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"G Targher","year":"2020","journal-title":"Gut"},{"key":"pone.0299507.ref004","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.","volume":"15","author":"Z Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"pone.0299507.ref005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/gast.2001.25540","article-title":"Nonalcoholic Fatty Liver Disease: Predictors of Nonalcoholic Steatohepatitis and Liver Fibrosis in the Severely Obese","volume":"121","author":"JB Dixon","year":"2001","journal-title":"Gastroenterology"},{"issue":"4","key":"pone.0299507.ref006","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030,","volume":"69","author":"C Estes","year":"2018","journal-title":"Journal of Hepatology"},{"key":"pone.0299507.ref007","first-page":"778","volume":"71","author":"A Mantovani","year":"2022","journal-title":"Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies Gut"},{"key":"pone.0299507.ref008","article-title":"Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of extrahepatic cancer","author":"C Roderburg","year":"2022","journal-title":"Gut"},{"issue":"7","key":"pone.0299507.ref009","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/apt.17165","article-title":"Extrahepatic morbidities and mortality of NAFLD: an umbrella review of meta-analyses","volume":"56","author":"M Yi","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"pone.0299507.ref010","doi-asserted-by":"crossref","first-page":"e1001680","DOI":"10.1371\/journal.pmed.1001680","article-title":"Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis.","volume":"11","author":"G Musso","journal-title":"PLOS Medicine"},{"issue":"6","key":"pone.0299507.ref011","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.2337\/dc13-2704","article-title":"Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes","volume":"37","author":"G Targher","year":"2014","journal-title":"Diabetes Care"},{"issue":"3","key":"pone.0299507.ref012","doi-asserted-by":"crossref","first-page":"199","DOI":"10.4082\/kjfm.2013.34.3.199","article-title":"Non-alcoholic Fatty Liver Disease and Chronic Kidney Disease in Koreans Aged 50 Years or Older.","volume":"34","author":"AL Ahn","year":"2013","journal-title":"Korean J Fam Med."},{"key":"pone.0299507.ref013","doi-asserted-by":"crossref","first-page":"E606","DOI":"10.1111\/j.1399-0012.2011.01497.x","article-title":"Implications of worse renal dysfunction and medical comorbidities in patients with NASH undergoing liver transplant evaluation: impact on MELD and more","volume":"25","author":"CW Park","journal-title":"Clinical Transplantation"},{"key":"pone.0299507.ref014","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1445-5994.2009.01979.x","article-title":"Impact of non-alcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes","volume":"40","author":"ST Hwang","year":"2010","journal-title":"Internal Medicine Journal"},{"key":"pone.0299507.ref015","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00125-010-1720-1","article-title":"Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients","volume":"53","author":"G Targher","year":"2010","journal-title":"Diabetologia"},{"key":"pone.0299507.ref016","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s00125-007-0897-4","article-title":"Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative\/laser-treated retinopathy in type 2 diabetic patients","volume":"51","author":"G Targher","year":"2008","journal-title":"Diabetologia"},{"issue":"6","key":"pone.0299507.ref017","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jhep.2017.08.024","article-title":"Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: A cohort study","volume":"67","author":"DH Sinn","year":"2017","journal-title":"Journal of Hepatology"},{"key":"pone.0299507.ref018","author":"KWM Abeysekera","year":"2023","journal-title":"Exploring changing attitudes to non-invasive liver fibrosis tests in secondary care pathways: comparison of two national surveys Frontline Gastroenterology Published Online First"},{"issue":"4","key":"pone.0299507.ref019","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jhep.2020.01.013","article-title":"NAFLD as a driver of chronic kidney disease","volume":"72","author":"CD Byrne","year":"2020","journal-title":"Journal of Hepatology"},{"issue":"4","key":"pone.0299507.ref020","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3390\/ijms17040562","article-title":"NAFLD and Chronic Kidney Disease","volume":"17","author":"M Marcuccilli","year":"2016","journal-title":"International Journal of Molecular Sciences"},{"issue":"4","key":"pone.0299507.ref021","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jhep.2019.05.033","article-title":"Intelligent liver function testing (ilft): A trial of automated diagnosis and staging of liver disease in primary care.","volume":"71","author":"JF Dillon","year":"2019","journal-title":"Journal of Hepatology"},{"key":"pone.0299507.ref022","article-title":"Scottish Government Health Board Data: Tayside","journal-title":"statistics.gov.scot."},{"key":"pone.0299507.ref023","first-page":"10.1097\/HEP.0000000000000520","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature [published online ahead of print, 2023 Jun 24]","author":"ME Rinella","year":"2023","journal-title":"Hepatology"},{"key":"pone.0299507.ref024","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"KDIGO CKD Work Group","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"pone.0299507.ref025","volume-title":"British National Formulary.","author":"Joint Formulary Committee","year":"2010","edition":"6"},{"issue":"16","key":"pone.0299507.ref026","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/hc4101.096153","article-title":"Renal considerations in angiotensin converting enzyme inhibitor therapy","volume":"104","author":"AC Schoolwerth","year":"2001","journal-title":"Circulation"},{"issue":"10","key":"pone.0299507.ref027","first-page":"CD011339","article-title":"Diuretics for people with chronic kidney disease.","volume":"2017","author":"PB Shah","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"issue":"3","key":"pone.0299507.ref028","doi-asserted-by":"crossref","first-page":"246","DOI":"10.7861\/clinmedicine.4-3-246","article-title":"Protecting and using patient information: the role of the Caldicott Guardian.","volume":"4","author":"A Greenough","year":"2004","journal-title":"Clin Med (Lond)."},{"key":"pone.0299507.ref029","article-title":"UK Policy Framework for defining Health and Social Care Research","year":"2017","journal-title":"Health Research Authority"},{"key":"pone.0299507.ref030","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1002\/bimj.202100254","article-title":"On the choice of timescale for other cause mortality in a competing risk setting using flexible parametric survival models","volume":"64","author":"N Skourlis","year":"2022","journal-title":"Biometrical Journal"},{"key":"pone.0299507.ref031","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1002\/sim.5347","article-title":"Use of alternative time scales in Cox proportional hazard models: implications for time-varying environmental exposures","volume":"31","author":"BA Griffin","year":"2012","journal-title":"Statist. Med."},{"key":"pone.0299507.ref032","article-title":"Longitudinal outcomes associated with metabolic dysfunction-associated steatotic liver disease: A meta-analysis of 129 studies\u2019","author":"KE Chan","year":"2023","journal-title":"Clinical Gastroenterology and Hepatology [Preprint]."},{"issue":"6","key":"pone.0299507.ref033","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1007\/s10620-021-07032-z","article-title":"Comorbidities Are Associated with Fibrosis in NAFLD Subjects: A Nationwide Study (NASH-CO Study).","volume":"67","author":"O Nabi","year":"2022","journal-title":"Dig Dis Sci"},{"issue":"17","key":"pone.0299507.ref034","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"AJ Sanyal","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"pone.0299507.ref035","doi-asserted-by":"crossref","first-page":"101497","DOI":"10.1016\/j.diabet.2023.101497","article-title":"MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus","volume":"50","author":"A Mantovani","year":"2024","journal-title":"Diabetes & Metabolism."},{"key":"pone.0299507.ref036","article-title":"Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease","author":"H Lee","year":"2023","journal-title":"Gut Published Online First:"},{"issue":"1","key":"pone.0299507.ref037","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"ZM Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"47","key":"pone.0299507.ref038","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.3748\/wjg.v23.i47.8263","article-title":"Clinical epidemiology and disease burden of nonalcoholic fatty liver disease","volume":"23","author":"BJ Perumpail","year":"2017","journal-title":"World J Gastroenterol"},{"key":"pone.0299507.ref039","article-title":"Changing from NAFLD TO MASLD: The new definition can more accurately identify individuals at higher risk for diabetes","author":"L He","year":"2023","journal-title":"Journal of Hepatology"},{"key":"pone.0299507.ref040","doi-asserted-by":"crossref","first-page":"m2687","DOI":"10.1136\/bmj.m2687","article-title":"Hepatorenal syndrome: pathophysiology, diagnosis, and management","volume":"370","author":"A Simonetto D","year":"2020","journal-title":"BMJ"},{"issue":"2","key":"pone.0299507.ref041","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jhep.2021.09.029","article-title":"Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it?","volume":"76","author":"G Baffy","year":"2021","journal-title":"Journal of Hepatology"},{"key":"pone.0299507.ref042","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-022-00559-y","article-title":"Glomerular hyperfiltration.","volume":"18","author":"M Cortinovis","year":"2022","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"pone.0299507.ref043","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/j.dld.2023.01.094","article-title":"Glomerular Hyperfiltration is a new marker of fibrosis severity in non-cirrhotic NAFLD","volume":"55","author":"A Dalbeni","year":"2023","journal-title":"Digestive and Liver Disease"},{"issue":"1","key":"pone.0299507.ref044","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12882-016-0386-4","article-title":"Central obesity associates with renal hyperfiltration in the non-diabetic general population: a cross-sectional study.","volume":"17","author":"VT Stefansson","year":"2016","journal-title":"BMC Nephrol"},{"key":"pone.0299507.ref045","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12916-023-02891-x","article-title":"The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank","volume":"21","author":"TJ Hydes","year":"2023","journal-title":"BMC Med"},{"key":"pone.0299507.ref046","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1038\/s41598-018-23014-0","article-title":"Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study","volume":"8","author":"HR Jang","year":"2018","journal-title":"Sci Rep"},{"issue":"2","key":"pone.0299507.ref047","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00592-022-01978-w","article-title":"Metabolic-associated fatty liver disease increases the risk of end-stage renal disease in patients with biopsy-confirmed diabetic nephropathy: a propensity-matched cohort study","volume":"60","author":"Y Zou","year":"2023","journal-title":"Acta Diabetol"},{"issue":"5","key":"pone.0299507.ref048","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic Fatty Liver Disease: Systematic review and meta\u2010analysis","volume":"65","author":"PS Dulai","year":"2017","journal-title":"Hepatology"},{"issue":"2","key":"pone.0299507.ref049","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/ageing\/afx184","article-title":"Patterns of multi-morbidity and prediction of hospitalisation and all-cause mortality in advanced age.","volume":"47","author":"RO Teh","year":"2018","journal-title":"Age Ageing."},{"issue":"10225","key":"pone.0299507.ref050","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: A systematic analysis for the global burden of disease study 2017","volume":"395","author":"B Bikbov","year":"2020","journal-title":"The Lancet"},{"issue":"3","key":"pone.0299507.ref051","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230512","article-title":"The impact of chronic kidney disease on developed countries from a health economics perspective: A systematic scoping review.","volume":"15","author":"S Elshahat","year":"2020","journal-title":"PLOS ONE"},{"issue":"4","key":"pone.0299507.ref052","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.","volume":"77","author":"ZM Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"pone.0299507.ref053","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","article-title":"A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes","volume":"78","author":"V Ajmera","year":"2023","journal-title":"J Hepatol"},{"key":"pone.0299507.ref054","doi-asserted-by":"crossref","first-page":"c5869","DOI":"10.1136\/bmj.c5869","article-title":"Population based screening for chronic kidney disease: cost effectiveness study","volume":"341","author":"B Manns","year":"2010","journal-title":"BMJ"},{"issue":"5","key":"pone.0299507.ref055","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials","volume":"67","author":"X Xie","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"pone.0299507.ref056","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/apt.15673","article-title":"Modelling NAFLD disease burden in four Asian regions\u20142019\u20132030.","volume":"51","author":"C Estes","journal-title":"Aliment Pharmacol Ther. 2020"},{"issue":"1","key":"pone.0299507.ref057","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jhep.2023.01.026","article-title":"Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties","volume":"79","author":"AM Allen","year":"2023","journal-title":"J Hepatol"},{"issue":"5","key":"pone.0299507.ref058","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"ME Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"pone.0299507.ref059","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"EASL\u2013EASD\u2013EASO","year":"2016","journal-title":"Journal of Hepatology"},{"issue":"8","key":"pone.0299507.ref060","doi-asserted-by":"crossref","first-page":"E158","DOI":"10.1503\/cmaj.150653","article-title":"Routinely collected data and comparative effectiveness evidence: promises and limitations.","volume":"188","author":"LG Hemkens","year":"2016","journal-title":"CMAJ"},{"key":"pone.0299507.ref061","article-title":"Type 2 Diabetes; Diagnosis in adults (NICE guidelines).","year":"2023","journal-title":"NICE"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0299507","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T13:48:56Z","timestamp":1713275336000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0299507"}},"subtitle":[],"editor":[{"given":"Anna","family":"Di Sessa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":61,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0299507","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,16]]}}}